Journal article
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY
Abstract
PurposeThe interim analysis of the phase IIIb LUCY trial demonstrated the clinical effectiveness of olaparib in patients with germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC), with median progression-free survival (PFS) of 8.11 months, which was similar to that in the olaparib arm of the phase III OlympiAD trial (7.03 months). This prespecified analysis provides final …
Authors
Koynova T; Popov V; Timcheva C; Tomova A; Eisen A; Gelmon K; Lemieux J; Augereau P; Bazan F; Becuwe C
Journal
Breast Cancer Research and Treatment, Vol. 204, No. 2, pp. 237–248
Publisher
Springer Nature
Publication Date
April 2024
DOI
10.1007/s10549-023-07165-x
ISSN
0167-6806